111 related articles for article (PubMed ID: 8702230)
1. Pharmacokinetics of a new platinum compound, cis-(glycolato-O,O) [(4R,5R)-4,5-bis(aminomethyl)-1,3-dioxolane-2-spiro-1'-cyclohexane]plat inum (II) in dogs.
Kim DK; Cho YB; Kim HT; Kim TS; Kim KH; Hong WS
Anticancer Res; 1996; 16(3A):1167-9. PubMed ID: 8702230
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of platinum following the administration of cis-(glycolato-O,O')[(4R,5R)-4,5-bis(aminomethyl)-2-isopropyl-1, 3-dioxolane]platinum(II) in dogs.
Kim DK; Kim HT; Cho YB; Kim TS; Kim KH; Hong WS
Anticancer Res; 1997; 17(5A):3681-3. PubMed ID: 9413223
[TBL] [Abstract][Full Text] [Related]
3. In vitro cytotoxicity, pharmacokinetics and ex vivo pharmacodynamics of a new platinum compound, cis-malonato [(4R,5R-4,5-bis(aminomethyl)-1,3-dioxolane-2-spiro-1'-cyclopentane] platinum (II).
Kim DK; Kim HT; Cho YB; Kim TS; Kim KH; Hong WS
Anticancer Res; 1996; 16(1):251-6. PubMed ID: 8615617
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics, tissue distribution, and excretion of cis-malonato[(4R,5R)-4,5-bis(aminomethyl)-2-isopropyl-1,3- dioxolane]platinum(II) in dogs.
Cho YB; Kim KH; Kim DK
Drug Metab Dispos; 1995 Nov; 23(11):1280-5. PubMed ID: 8591731
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics and antitumor activity of a new platinum compound, cis-malonato[(4R,5R)-4,5-bis(aminomethyl)-2-isopropyl-1, 3- dioxolane]platinum(II), as determined by ex vivo pharmacodynamics.
Kim DK; Kim HT; Tai JH; Cho YB; Kim TS; Kim KH; Park JG; Hong WS
Cancer Chemother Pharmacol; 1995; 37(1-2):1-6. PubMed ID: 7497577
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of cis-malonato[(4R,5R)-4,5-bis(aminomethyl)-2-isopropyl-1, 3-dioxolane]platinum(II) in rats.
Cho YB; Kim DK; Kim KH; Miyamoto G
Arzneimittelforschung; 1996 Jun; 46(6):629-34. PubMed ID: 8767356
[TBL] [Abstract][Full Text] [Related]
7. Mammary excretion and placental transfer of cis-malonato[(4R,5R)-4,5-bis(aminomethyl)-2-isopropyl-1,3-dioxolane] platinum(II) in rats.
Cho YB; Kim KH; Kim DK; Miyamoto G
Arzneimittelforschung; 1996 Sep; 46(9):926-30. PubMed ID: 8876944
[TBL] [Abstract][Full Text] [Related]
8. Influence of exposure and infusion times on the cytotoxicity and pharmacokinetics of cis-malonato[(4R, 5R)-4,5-bis(aminomethyl)-2-isopropyl-1,3-dioxolane]platinum(II) .
Kim HT; Kim DK; Cho YB; Kim TS; Jung I; Kim KH; Heo DS; Bang YJ; Shin SG; Kim NK
Cancer Chemother Pharmacol; 1998; 41(2):109-16. PubMed ID: 9443623
[TBL] [Abstract][Full Text] [Related]
9. A Phase I study of cis-malonato[(4R,5R)-4,5-bis(aminomethyl)-1,3-dioxolane] platinum(II) in patients with advanced malignancies.
Kim NK; Kim TY; Shin SG; Park YI; Lee JA; Cho YB; Kim KH; Kim DK; Heo DS; Bang YJ
Cancer; 2001 Apr; 91(8):1549-56. PubMed ID: 11301404
[TBL] [Abstract][Full Text] [Related]
10. General pharmacology of cis-malonato[4R,5R)-4,5-bis-(aminomethyl)-2-isopropyl-1,3- dioxolane]platinum(II).
Kim DK; Ahn JS; Ryu G; Kim KH; Park CW; Kim MS; Chung MH; Shin SG; Suh YH; Kim YS
Arzneimittelforschung; 1994 Sep; 44(9):1080-8. PubMed ID: 7986249
[TBL] [Abstract][Full Text] [Related]
11. cis-Amminedichloro(2-methylpyridine) platinum(II) (AMD473), a novel sterically hindered platinum complex: in vivo activity, toxicology, and pharmacokinetics in mice.
Raynaud FI; Boxall FE; Goddard PM; Valenti M; Jones M; Murrer BA; Abrams M; Kelland LR
Clin Cancer Res; 1997 Nov; 3(11):2063-74. PubMed ID: 9815598
[TBL] [Abstract][Full Text] [Related]
12. In vitro antitumor activity of a new platinum complex, cis-malonato [(4R,5R)-4,5-bis(aminomethyl)-2-isopropyl-1,3-dioxolane] platinum (II) (SKI 2053R), against human lung and stomach cancer cell lines.
Hong WS; Kim HT; Kim KH; Kim DK
Anticancer Res; 1995; 15(1):51-4. PubMed ID: 7733640
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of platinum in cancer patients following intravenous infusion of cis-diammine(glycolato)platinum, 254-S.
Ota K; Oguma T; Shimamura K
Anticancer Res; 1994; 14(3B):1383-7. PubMed ID: 8067710
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics and tissue distribution of novel traditional Chinese medicine-platinum anticancer agents in rats.
Wang X; Au-Yeung SC; Ho YP
J Inorg Biochem; 2007 Jun; 101(6):909-17. PubMed ID: 17428541
[TBL] [Abstract][Full Text] [Related]
15. cis-[(4R,5R)-4,5-bis(aminomethyl)-2,2-dimethyl-1,3-dioxolane-N,N']- (malonato-O,O')platinum(II), an anticancer agent.
Cho SW; Cho Y; Kim DK; Shin W
Acta Crystallogr C; 2000 Jun; 56(Pt 6):653-4. PubMed ID: 10902008
[No Abstract] [Full Text] [Related]
16. Distribution and disposition of platinum following intravenous administration of cis-diamminedichloroplatinum(II) (NSC 119875) to dogs.
Litterst CL; Gram TE; Dedrick RL; Leroy AF; Guarino AM
Cancer Res; 1976 Jul; 36(7 PT 1):2340-4. PubMed ID: 1277140
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of oxaliplatin in patients with severe hepatic dysfunction.
Baur M; Drescher A; Gneist M; Dittrich C; Jaehde U
Cancer Chemother Pharmacol; 2008 Jan; 61(1):97-104. PubMed ID: 17396265
[TBL] [Abstract][Full Text] [Related]
18. Plasma and cerebrospinal fluid pharmacokinetics of intravenous oxaliplatin, cisplatin, and carboplatin in nonhuman primates.
Jacobs SS; Fox E; Dennie C; Morgan LB; McCully CL; Balis FM
Clin Cancer Res; 2005 Feb; 11(4):1669-74. PubMed ID: 15746072
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of oxaliplatin (NSC 266046) alone and in combination with paclitaxel in cancer patients.
Liu J; Kraut E; Bender J; Brooks R; Balcerzak S; Grever M; Stanley H; D'Ambrosio S; Gibson-D'Ambrosio R; Chan KK
Cancer Chemother Pharmacol; 2002 May; 49(5):367-74. PubMed ID: 11976830
[TBL] [Abstract][Full Text] [Related]
20. [Pharmacokinetics of cis-diammine (glycolato) platinum (254-S), a new platinum antitumor agent, following an intravenous and intraperitoneal infusion bioactive platinum concentration profile].
Hirabayashi K; Okada E; Oguma T; Shimamura K
Gan To Kagaku Ryoho; 1990 Nov; 17(11):2221-7. PubMed ID: 2241186
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
